Total Funding
69
56
Total FundingSeries B raised
Growth Score
-3 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
7668
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.
- Miguel Arcinas: Chief Business OfficerPast Role: Acadia Pharmaceuticals Inc., Sr. Manager, Corporate Development
- Ramin Farzaneh-Far: Chief Medical Officer
About the Company
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases using its proprietary CellSeeker tLNP platform. Its technology deploys targeted lipid nanoparticles conjugated with protein binders—such as antibodies—to reprogram specific cell types within the body, including CAR-T cells, without ex vivo
manipulation. The lead candidate, CPTX2309, delivers an anti-CD19 CAR payload to CD8⁺ T cells and aims to reset B cell–driven autoimmune disease, currently in Phase 1 trials.
